Q1 2024 Earnings Estimate for Sanofi (NASDAQ:SNY) Issued By Leerink Partnrs

Sanofi (NASDAQ:SNY) – Equities researchers at Leerink Partnrs cut their Q1 2024 earnings per share estimates for shares of Sanofi in a report issued on Tuesday, April 16th. Leerink Partnrs analyst D. Risinger now expects that the company will earn $0.94 per share for the quarter, down from their prior estimate of $0.98. The consensus estimate for Sanofi’s current full-year earnings is $4.16 per share. Leerink Partnrs also issued estimates for Sanofi’s FY2024 earnings at $3.97 EPS, FY2025 earnings at $4.44 EPS and FY2028 earnings at $5.34 EPS.

A number of other equities analysts have also weighed in on SNY. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Morgan Stanley began coverage on Sanofi in a research note on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 target price on the stock. Finally, TheStreet lowered Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Sanofi has an average rating of “Hold” and an average price target of $55.00.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $45.39 on Thursday. The firm has a market capitalization of $114.82 billion, a P/E ratio of 19.23, a P/E/G ratio of 1.71 and a beta of 0.61. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The stock’s 50-day simple moving average is $47.52 and its two-hundred day simple moving average is $48.67. Sanofi has a twelve month low of $42.63 and a twelve month high of $57.82.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The business had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be given a dividend of $1.478 per share. The ex-dividend date of this dividend is Thursday, May 9th. This is a positive change from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. Sanofi’s dividend payout ratio is 58.47%.

Hedge Funds Weigh In On Sanofi

Several institutional investors have recently modified their holdings of SNY. Arrowstreet Capital Limited Partnership grew its position in Sanofi by 276.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company’s stock worth $172,611,000 after acquiring an additional 2,468,271 shares during the last quarter. Morgan Stanley grew its position in Sanofi by 19.3% during the 4th quarter. Morgan Stanley now owns 7,733,069 shares of the company’s stock worth $374,513,000 after acquiring an additional 1,251,199 shares during the last quarter. Armistice Capital LLC bought a new position in Sanofi during the 4th quarter worth approximately $51,520,000. Perceptive Advisors LLC bought a new position in Sanofi during the 1st quarter worth approximately $41,800,000. Finally, Point72 Asset Management L.P. bought a new position in Sanofi during the 4th quarter worth approximately $38,108,000. 10.04% of the stock is currently owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.